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Abstract 
Two novel sandwich-based immunoassays for prostate cancer (PCa) diagnosis are reported, in which 
the primary antibody for capture is replaced by a DNA aptamer. The assays, which can be performed 
in parallel, were developed in a microfluidic device and tested for the detection of free Prostate 
Specific Antigen (fPSA). A secondary antibody (Aptamer-Antibody Assay) or a lectin (Aptamer-
Lectin Assay) is used to quantify, by chemiluminescence, both the amount of fPSA and its 
glycosylation levels. The use of aptamers enables a more reliable, selective and controlled sensing of 
the analyte. The dual approach provides sensitive detection of fPSA along with selective fPSA 
glycoprofiling, which is of significant importance in the diagnosis and prognosis of PCa, as tumor 
progression is associated with changes in fPSA glycosylation. With these approaches, we can 
potentially detect 0.5 ng/mL of fPSA and 3 ng/mL of glycosylated fPSA using Sambucus nigra 
(SNA) lectin, both within the relevant clinical range. The approach can be applied to a wide range of 
biomarkers, thus providing a good alternative to standard antibody-based immunoassays with 
significant impact in medical diagnosis and prognosis. 
 
Keywords: Microfluidics, DNA aptamer, Glycoprofiling, Sandwich assay, ELISA, Prostate cancer. 
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1. Introduction 
Cancer is one of the leading causes of mortality worldwide. When diagnosed accurately and at an 
early stage, better monitoring and successful treatment of the disease can be achieved (Zieglschmid et 
al. 2005). Therefore, there is a high demand for improved diagnosis and prognosis tools. The quest for 
early diagnosis of cancer with high sensitivity and accuracy has led to increasing work on the 
detection of multiple biomarkers (Ploussard et al. 2011; Velonas et al. 2013). At the same time, one of 
the fields that have been gaining tremendous attention is that of glycomics for clinical diagnosis. The 
phenomenon of glycosylation, the covalent attachment of carbohydrate moieties to proteins and lipids, 
is one of the most abundant and complex post-translational modifications of proteins in human body. 
These modifications are involved in numerous physiological regulatory processes (Rudd et al. 2001; 
Rudd et al. 1999; Shental-Bechor and Levy 2009) including cancer (Gilgunn et al. 2013; Christiansen 
et al. 2014). Since glycosylation is a hallmark of disease states, altered glyco-forms may serve as 
viable candidate biomarkers for early-stage cancer diagnosis (Adamczyk et al. 2012; Pihíková et al. 
2015). It is believed that the simultaneous detection of protein biomarkers and their glycosylation 
levels is a powerful tool for cancer diagnosis and prognosis. 
Protein glycoprofiling can be performed either directly or indirectly after glycan release from intact 
glycoproteins. The released glycans can be further analyzed using a variety of commonly used 
analytical techniques such as HPLC, capillary electrophoresis and mass spectroscopy, which are 
laborious and expensive (Adamczyk et al. 2014; Domann et al. 2007; Thaysen-Andersen and Packer 
2014). On the other hand, direct glycoprofiling methods are based on biorecognition elements such as 
lectins (Katrlik et al. 2010), anti-carbohydrate antibodies (Smith and Cummings 2010) or other glycan 
binding proteins capable of recognizing specific glycan structures. However, approaches based on the 
use of proteins (antibodies, lectins) have limitations such as cross-reactivity of the recognition 
element with some components present in the sample resulting in false positives. Additionally, using 
antibodies for diagnostic applications have drawbacks such as high costs, poor stability over time and 
difficulty in engineering them to suit the sensing platforms (Haupt and Mosbach 2000). One alternate 
promising class of receptor that can address many of these issues is aptamers, which are short 
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oligonucleotide sequences that can strongly bind to their target with high affinity and specificity by 
undergoing conformational changes. Selection of aptamers is an in vitro process (SELEX) and once 
selected, they can be synthesized in a controlled fashion with high purity and reproducibility. 
Additionally, aptamers are chemically more stable than antibodies, retaining most of their 
functionality even after multiple regeneration steps (Bunka and Stockley 2006; Jolly et al. 2014; 
O'Sullivan 2002; Song et al. 2008). As oligonucleotides can be easily modified with different reactive 
chemical groups, their immobilization on surfaces can be easily controlled, unlike antibodies. Because 
of the numerous advantages over antibodies, aptamers have been studied as emerging bioreceptors for 
the design and optimization of novel aptamer-based enzyme-linked immunosorbent assay (ELISA) for 
development of biosensors (Toh et al. 2015). 
Replacing one or both of the antibodies in a classical ELISA has enabled development of refined 
assays which are more robust, reproducible and economical (Tennico et al. 2010; Toh et al. 2015). 
Such modified ELISA methods have also been demonstrated in microfluidics, which holds promise in 
biomedical research especially as a potential point-of-care (PoC) device. Su et al. recently reported an 
electrochemical lab-on-paper cyto-device to demonstrate specific cancer cell detection as well as 
monitoring of the multi-glycans on living cancer cells (Su et al. 2015). Liu et al. reported an aptamer-
based ELISA approach for detection of rare cells with chemiluminescence (CL) analysis. (Liu et al. 
2011). Yang et al. reported the development of aptamer based ELISA assay for C reactive protein 
using magnetic beads in a microfluidic system (Yang et al. 2009). 
In this study, we report for the first time the development of aptamer-based ELISA for quantification 
of free prostate specific antigen (fPSA) in a microfluidic device. PSA is a 33 kDa serine protease 
(kallikrein-3) secreted by the prostate gland and high concentrations above the cut-off value of 
4 ng/ml in blood are often associated with prostate cancer (PCa) thus leading to the consideration of 
further biopsy procedures (Catalona et al. 1991). However, the levels of PSA in blood in ageing men 
can also be raised due to other factors such as benign prostatic hyperplasia (BPH) and prostatitis. 
These factors lead to over-diagnosis (Carter et al. 1992) and as a result of false diagnosis, patients 
need to undergo unnecessary biopsy surgery, which is painful and also makes the patients vulnerable 
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to infections, making PSA testing a controversial diagnostic procedure. Nevertheless, PSA is still the 
most commonly used biomarker by clinicians for the detection of PCa and has thus motivated and led 
to the refinement of the PSA tests (Filella and Gimenez 2013; Kuriyama et al. 1998; Shariat et al. 
2011; Wians et al. 2002). 
Along with quantification of fPSA, glycoprofiling could effectively serve as a complementary 
procedure for enhanced diagnosis and monitoring of PCa and potentially reduce the levels of false 
positives through blood tests. Thus, we also report for the first time, multi-glycan profiling of fPSA 
using an aptamer-based sandwich assay in a microfluidic chemiluminescence sensor. Since PSA is a 
glycoprotein with various glycoforms (Isono et al. 2002; Végvári et al. 2012; Vermassen et al. 2012) 
the determination of cancer-associated glycoforms of PSA might help to improve early-stage clinical 
diagnosis of PCa (Meany and Chan 2011). There are studies in the literature showing that altered 
glycosylation patterns allow to distinguish healthy men from those with PCa or BPH (Peracaula et al. 
2003; Tabares et al. 2006; Tajiri et al. 2008). The key aspect of this work is not only the development 
of an aptamer-based ELISA for dual quantification and glycoprofiling of fPSA but also the simplicity 
of the microfluidic assay developed and its potential integration in a PoC device. Because of the 
aptamers’ advantages in terms of controlled orientation and smaller size, the fabricated biosensor 
could potentially detect 0.5 ng/mL of PSA along with distinct differentiation of different glycans 
involved in PCa. 
 
2. Materials and Methods 
2.1 Instruments and reagents 
Amine terminated PSA specific DNA aptamer (5’-H3N-(CH2)6-TTT TTA ATT AAA GCT CGC CAT 
CAA ATA GCT TT-3’), amine terminated PSA specific DNA aptamer labelled with Cy5 (5’-H3N-
(CH2)6-TTT TTA ATT AAA GCT CGC CAT CAA ATA GCT TT-Cy5-3’) and a random DNA 
sequence non-specific to PSA (5’-H3N-(CH2)6-AAA AAT TAA TTT CGA GCG GTA GTT TAT 
CGA AA-3’) used as control DNA were obtained from Sigma Aldrich, UK. Prostate specific antigen 
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(PSA) from human semen was obtained from Fitzgerald (MA, USA). Human glandular kallikrein 2 
(hK2) was obtained from RnD systems, UK. Phosphate buffered saline (PBS) tablets, (3-
Glycidyloxypropyl)trimethoxysilane, Ethanolamine, human serum albumin (HSA), andwere all 
purchased from Sigma-Aldrich, Portugal. Streptavidin-HRP was purchased from Invitrogen Life 
Technologies (MA, USA). Luminol, Pierce (Supersignal® West Femto Substrate Trial Kit – 34094 
and Supersignal West Pico – 35065) was used as purchased from Thermo Scientific, Portugal. In 
addition, anti-equimolar total PSA-HRP antibodies (Ab178776) were purchased from Abcam. Both 
lectins SNA (Sambucus nigra agglutinin) and MAA II (Maackia amurensis lectin II) were obtained 
from VectorLab. All reagents were of analytical grade. All aqueous solutions were prepared using 
18.2 MΩ cm ultra-pure water from a Milli Q system (Millipore, MA, USA). All the antibodies were 
diluted in 10 mM PBS (pH 7.4) filtered through a 0.4 µm syringe filter. Metallic plug adapters for the 
microchannel and capillary tubing (BTPE-90) were purchased from Instech Solomon (PA, USA). 
1 mL syringes were from CODAN, Germany. The liquid flow in the microchannel was controlled 
using a NE-300 syringe pump from New Era (NY, USA).  
 
2.2 Fabrication of PDMS Microchannel structures 
The fabrication of the polydimethylsiloxane (PDMS) microchannels was performed using soft 
lithography. Fabrication of hard mask, SU-8 mold and PDMS devices were adapted from literature as 
described by Soares et al. (2014). Briefly, SU-8 (Microchem, Newton, USA) was used to transfer the 
patterns of an aluminum mask to a silicon mold with a negative photoresist along with UV exposure 
and development in propylene glycol monomethyl ether acetate (Sigma-Aldrich, Portugal). Later, the 
mold patterns were transferred to PDMS to obtain the microfluidic devices for the experiments. The 
PDMS devices consisting of microchannels with width, w = 200 µm, height, h = 20 µm and length, 
l = 1 cm were sealed to a cleaned glass substrate via an UV-ozone treatment for 6 min at 28-
32 mW/cm2 (UVO cleaner 144AX, Jelight Company Inc., CA, USA) for surface oxidation. 
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2.3 Microfluidic Aptamer Assays 
Surface functionalization of aptamers for both fPSA quantification and glycoprofiling studies were 
performed according to the schematics shown in Fig. 1. Briefly, the microfluidic channel was first 
functionalized with pure solution of (3-Glycidyloxypropyl) trimethoxysilane at a flow rate of 
Q = 0.3 µL/min for 15 min, followed by 5 min washing with milliQ water at Q = 5 µL/min to remove 
all non-specifically bound silane molecules. Then, a 10 µM solution of DNA aptamer prepared in 
PBS was flowed at 0.4 µL/min for different time spans ranging from 5 to 30 min in order to optimize 
the aptamers surface density towards maximum PSA binding. The channel was then washed with PBS 
at a flow rate of Q = 5 µL/min for 2 min to remove any non-specifically bound aptamers, followed by 
ethanolamine blocking (10 mM in PBS, pH 8.5) at Q = 0.5 µL/min for 15 min. Finally, the channel 
was washed with PBS at Q = 5 µL/min for 2 min prior the assays. The subsequent analysis was 
always performed immediately after the immobilization procedure. For every individual experiment, 
new structures with fresh functionalization steps were performed. 
For the fPSA quantification assay, HRP labelled anti-PSA antibodies were used at a concentration of 
100 μg/mL. For the glycoprofiling assay, biotinylated lectins and streptavidin-HRP were used at a 
concentration of 100 μg/mL. 
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Fig. 1. Schematic of microfluidic channel fabrication scheme. 
 
2.4 Nanospotting of DNA aptamers on PDMS film 
The DNA aptamers labelled with Cyanine3 on the 3’ end were spotted on a thin PDMS film surface 
as detailed by Novo et al. A non-contact spotter (Nanoplotter NP2.1, GeSiM, Germany) was used to 
spot different concentration of DNA aptamer solutions with a piezoelectric pipette (Pico tip with a 
capacity to dispense single droplets with volumes down to ∼56 pL) mounted on a computer controlled 
stage (Novo et al. 2011). The total number of times a droplet solution was dispensed and the degree of 
hydrophilicity of the ozone treated PDMS film at a particular location determines the diameter and the 
amount of DNA aptamers at that spot. The temperature was fixed at 16 °C and humidity was adjusted 
to near the dew point to increase the evaporation time of the droplets, ensuring homogeneous drying. 
 
2.5 Image acquisition and analysis 
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A fluorescence microscope (Leica DMLM) connected to a digital camera (Leica DFC300FX) was 
used for imaging the microchannels and recording the signal. The chemiluminescent signal was 
acquired using a microscope after flowing luminol Q = 5 µL/min for 1min, with an exposure time of 
10 s and 10x optical gain, all in a dark background. The acquired images were analyzed using ImageJ 
software (National Institutes of Health, USA). The values correspond to the background normalized 
average measurements from three independent experiments, each with three regions of interest along 
the microchannel. 
 
3. Results and Discussion 
3.1 Optimization of DNA aptamer surface coverage 
Aiming at miniaturizing an assay for the quantification and glycoprofiling of f-PSA, it is essential to 
perform first an optimization of both the physical and chemical aspects of the biosensors, namely the 
microchannel dimensions, the flow-rates used, residence time and molecular immobilization 
strategies. The first three parameters were previously optimized and validated with a system using 
antibodies to capture PSA (Madaboosi et al. 2015) and used herein without further modification. 
Surface density of probes in particular plays a vital role in fabricating an efficient biosensor as 
reported with different techniques (Jolly et al. 2015; Keighley et al. 2008a; Keighley et al. 2008b; 
Madaboosi et al. 2015). An optimum spacing between the aptamers on the surface is required so that 
upon target capture, the aptamer can undergo conformational changes with minimal steric hindrance 
effects. In order to have efficient binding of PSA in the microfluidic channel via DNA aptamers, an 
optimization of the immobilization time of DNA aptamers was made. The optimization was 
performed using an antibody as a detector molecule, where fPSA was captured using DNA aptamers 
immobilized on the microfluidic channel, followed by detection with an anti-fPSA antibody labeled 
with the reporter enzyme horseradish peroxidase (anti-fPSA Ab-HRP). A fixed concentration of DNA 
aptamer equal to 10 µM in 10 mM PBS was flowed for different time intervals and a fixed fPSA 
concentration of 10 ng/mL was chosen for the experiment. From Fig. 2a, it can be seen that as we 
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increase the time of immobilization of DNA aptamers from 5 min to 15 min, an increase in the 
chemiluminescence signal was observed. 
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Fig. 2. Chemiluminescence signal with different time periods of DNA aptamer immobilization upon 
PSA binding, detected by anti-fPSA Ab-HRP (a). Nanospotting of DNA aptamer labelled with Cy3 to 
estimate the surface density. The inset image shows the optical micrograph of DNA aptamers labelled 
with Cy3 covalently immobilized in the microchannel (b). 
 
However, as the time was further increased to 30 min, the chemiluminescence signal was reduced. 
This may be explained by considering that the density of the DNA aptamer layer on the surface 
becomes too densely packed to allow further effective PSA binding due to steric hindrance effects 
(Formisano et al. 2015). Thus, to achieve an effective PSA detection, 15 min was chosen as the 
immobilization time for subsequent experiments. 
The relative coverage of the immobilized DNA aptamers on the surface of a microchannel was 
estimated from a nanospotting experiment. This method allows a robust and precise deposition of a 
controlled volume of DNA aptamers onto a surface using a computer-controlled microspotter (Novo 
et al. 2011). In the experiment, the aptamer solution is filled in a Pico tip that enables spots on the 
surface by dispensing the DNA aptamer solution in a non-contact mode (50 drops per spot). A 
calibration graph of the DNA aptamers labeled with Cy3 fluorophore (DNA aptamer-Cy3) was 
a b 
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obtained from fluorescence microscopy. Known volumes of varied concentrations of DNA aptamer-
Cy3 was spotted on a thin PDMS film. The fluorescence resulting from the adsorbed DNA aptamer-
Cy3 was measured in the spotted areas and the total number of DNA aptamers adsorbed per unit area 
was calculated. Each DNA aptamer occupies an area of 6.16 × 10-6 µm2 assuming that all the DNA 
aptamers are in their single stranded state and lying perpendicular to the surface, where a single 
stranded DNA has a hydro-dynamic radius of 1.4 nm. 
Data obtained can be used to make a correlation be-tween the total number of DNA aptamer-Cy3 in 
the spot and the fluorescence intensity from the spot. The curve obtained was then used for 
determining the surface density of the immobilized DNA aptamers in the microfluidic channel at a 
known concentration. Fig. 2b shows a correlation between the average fluorescent signal obtained 
from the spotting experiments and the DNA aptamer-Cy3 relative surface coverage, which can be 
used to estimate the surface density of the DNA aptamer molecules in a microfluidic channel used for 
PSA-specific experiments. The inset in Fig. 2b shows the fluorescence signal of a typical relative 
surface coverage when DNA aptamers are immobilized in a microchannel using GOPTS surface 
chemistry. The microchannel was prepared according to the protocol described in the methods section 
and the inset image represents one of the channel with immobilized DNA aptamer-Cy3 via GOPTS. A 
surface coverage of 1.37 × 1013 molecules/cm2 was estimated from the obtained fluorescence signal in 
the microchannel (PL signal: 12.80 + 1.68 a.u.) with the immobilized DNA aptamer-Cy3. 
 
3.2 Quantification of PSA 
The DNA aptamer functionalized microfluidic channel, as described in the fabrication section, was 
used for the quantification of fPSA. The assay was based on a sandwich ELISA format, where anti-
fPSA antibodies labeled with HRP were used to detect the fPSA captured by the immobilized DNA 
aptamers (Aptamer-Antibody Assay). A wide working range of fPSA concentrations ranging from 
0.01 ng/mL to 50 ng/mL were used in the current study. It is important to highlight that each assay 
was performed in a new microchannel immediately after immobilization, since PDMS structures with 
such small footprint can be easily produced in large numbers and disposability avoids the use of 
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complex generation procedures (such as those described in e.g. Damborsky et al. 2015) and potential 
accumulation of non-specific binding. As seen from Fig. 3, a significant increase in the 
chemiluminescence signals is observed between 1 ng/mL and 25 ng/mL of fPSA concentrations, 
which lies within the cutoff range (grey area) of PSA in blood. It can be immediately observed that 
the background signal is not limiting the detection sensitivity at the clinically relevant concentrations, 
while still being detectable using the CCD camera of the microscope. This confirms that the 
ethanolamine blocking works effectively in providing a fit-for-purpose level of non-specificity. 
 
0.01 0.1 1 10 100
0
20
40
60
80
100
N
o
rm
a
lis
e
d
 C
h
e
m
ilu
m
in
e
s
c
e
n
c
e
 (
a
.u
.)
PSA [ng/mL]
0.01 ng/mL fPSA
1 ng/mL fPSA
5 ng/mL fPSA
10 ng/mL fPSA
50 ng/mL fPSA
 
Fig. 3. Quantification of fPSA using anti-fPSA Ab-HRP. Images represent the chemiluminescence 
signals from microscopy. 
 
The response obtained for fPSA quantification follows a Hill dose-response equation of the type 
y = y0 + (ymax - y0) cn / (Kdn + cn) where c is the concentration. The dissociation constant (Kd) for the dose 
response was calculated as 9.82 ng/mL with a root mean square (RMS) value of 0.98. The value of 
ymax which is the end value calculated from the fitting was 92.17 a.u. with n = 1.32. The fabricated 
biosensor could potentially differentiate 0.5 ng/mL of fPSA with a chemiluminescence value of 
11.90 + 1.49 a.u., which is higher than the y0 value (8.5 a.u.) calculated from the fitting. 
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3.3 Selectivity study 
The development of a reliable biosensor and its potential applications depends on many factors 
including selectivity. Various control experiments were investigated in order to confirm that the 
signals obtained with different PSA concentrations in the earlier section were due to specific capture 
of fPSA by the DNA aptamers immobilized on the microchannel surface. As the current study is a 
demonstration of the potential of an aptamer-based ELISA, it is important to test the role of aptamers 
as a probe to capture fPSA in the channel. This was performed by using two control experiments (see 
Fig. 4). In the first experiment, the silanized channel was blocked with ethanolamine, so that the 
aptamers were not eventually immobilized (Fig. 4, #3). In the second study, a random DNA of same 
length as of the PSA-specific DNA aptamer was immobilized on the microfluidic channel (Fig. 4, #4). 
The DNA aptamer specific to PSA used in this study was reported by Savory et al. (2010) where 
different DNA sequences were tested for the most efficient PSA binding sequence. Hence, for the 
current study, a random sequence was used as a control in order to demonstrate specific capture of 
fPSA and that there are no non-specific fPSA-DNA electrostatic interactions. It was done in order to 
confirm the role of DNA aptamer as a capture probe and to ensure that the signal is obtained only 
when fPSA has been captured by the aptamers. When the channel was observed under the 
microscope, a negligible change of less than 2 a.u. when compared with blank measurement was 
noticed.  
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Fig. 4. Selectivity studies for fPSA measurements. (1) Specific capture of fPSA (10 ng/mL) by DNA 
aptamers and thereafter, detected by anti-fPSA HRP. (2) Signal change when no fPSA was flowed. 
(3) Signal change when no aptamer was immobilized in the microchannel and 10 ng/mL fPSA was 
flowed. (4) When a random DNA sequence which is equivalent to the size of PSA specific DNA 
aptamer was used and 10 ng/mL fPSA was flowed (5) Signal change when 10 ng/mL hK2 was 
flowed. (6) Control with 4% HSA.  
 
We also performed two selectivity studies using the control proteins human Kallikrein 2 (hK2) 
(10 ng/mL) (fig. 4, #5) and human serum albumin (HSA) (4%) (fig. 4, #6). hK2 is another serine 
protease from the same kallikrein family as PSA. It was chosen as a control protein candidate of 
interest since it shares 80% homology with the PSA. The levels of hK2 are 100 fold lower than that of 
PSA in clinical samples; still this protein was stringently chosen since it served as an appropriate 
control to evaluate the aptamer-based approach over an antibody-based approach using ELISA (Hong 
2014; Vaisanen et al. 2006). With an aptamer-based ELISA system, an appreciable differentiation 
between hK2 and PSA can be noticed; the former when compared with blank showed a difference of 
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less than 2 a.u. only (fig. 4, #5). This can be distinctively differentiated from 10 ng/mL PSA (fig. 4, 
#1) with a difference of 55 a.u.  
As a comparison, classical ELISA was performed by adsorption of capture antibodies in the 
microfluidic channel and followed by the flow of 10 ng/mL hK2 protein, and finally a detector 
antibody labeled with HRP. The channel was then analyzed under a microscope. The results show a 
high level of cross reactivity of up to 20 a.u. and the inability of the antibodies to differentiate hK2 
from PSA. The high cross reactivity could be due to the fact that most of the antibodies raised against 
PSA exhibit certain cross-reactivity with the hK2 due to similar epitopic regions. Also, 4% HSA was 
used to test matrix interference effects and a slight decrease in chemiluminescence (~1 a.u.) was 
observed. This could be attributed to the blocking effect of HSA, leading to decreased non-specific 
binding of detector antibodies. 
 
3.4 Glycoprofiling of PSA  
The change in carbohydrate linkage of particular carbohydrate moieties such as sialic acid play a 
major role in glycoprofiling of PSA. It can indicate not only the presence of a pathological process 
but, more importantly, in some cases also its stage. Thus, a similar aptamer based assay design was 
also used for fPSA glycoprofiling, utilizing lectins as glyco-recognition elements rather than an anti-
PSA antibody (Aptamer-Lectin Assay). This is demonstrated by profiling the fPSA carbohydrate 
content using two biotinylated lectins specific for sialic acid: (i) Sambucus nigra lectin (SNA) binding 
preferentially to sialic acid attached to terminal galactose in α-2,6 linked sialic acid and (ii) Maackia 
amurensis lectin II (MAA II), a lectin recognizing terminal α-2,3 sialylation of PSA. The increase of 
α-2,3 linked sialic acid is highly presented in PCa patients (Ohyama et al. 2004).  
Since we employed commercial fPSA obtained from healthy donors, no interaction with MAA II 
lectin was expected. Thus, MAA II lectin was used as a negative control for a commercial non-
malignant fPSA. The fabricated biosensor using lectins was able to distinguish between α-2,6 linked 
sialic acid and α-2,3 linked sialic acid as shown in Fig. 5. This finding is in agreement with published 
studies (Saldova et al. 2011). The working range is slightly shifted when compared to quantification 
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experiments, the concentrations ranging from 3 ng/mL to 50 ng/mL fPSA. As seen from Fig. 5, the 
fabricated biosensor could potentially differentiate 3 ng/mL fPSA from the blank measurement with a 
difference of 5.64 + 0.50 a.u. using chemiluminescence. However, a significant increase in the 
chemiluminescence signal was observed between 5 ng/mL of PSA to 50 ng/mL of PSA concentration 
which lies within the cut-off range (grey zone) of PSA in the blood. Nevertheless, here the major 
focus was on the potential occurrence of sialic acid with different linkages on PSA surface in a 
multiglycan profiling approach, thus establishing the difference between the two lectin forms using an 
aptamer-based ELISA. 
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Fig. 5. Multi-glycan profiling for fPSA detection. Blue data points were obtained using a SNA lectin 
whereas, red data points were obtained using an MAA II (control) lectin. Images represent the 
chemiluminescence signals from microscopy.  
 
Again, a dose response fitting was performed using the same Hill equation that was used with 
quantification of PSA in Fig. 5, on the data points obtained with SNA lectin. A dissociation constant 
(Kd) of 12.5 ng/mL of PSA with a root mean square value of 0.99 was obtained. The value of ymax 
which is the end value calculated from the fitting was 72.08 a.u. with n = 1.96.  
17 
 
Considering the y0 value calculated to be 1.53 a.u. from the fitting, the fabricated biosensor could 
differentiate 3 ng/mL of fPSA with chemiluminescence value of 12.20 + 1.36 a.u.. In the control 
experiments, MAA II lectin did not show any binding to PSA in the whole concentration range 
studied. The differentiation in signal from the two lectins could be observed for fPSA concentrations 
above 3 ng/mL. 
 
4. Conclusions  
We present a simple novel aptamer based microfluidic ELISA assay for the optical detection of fPSA 
in the clinical range with high sensitivity. The integration of quantification of PSA with multi-glycan 
profiling of fPSA could serve as a potential platform for PoC devices in PCa diagnosis. We 
demonstrated a sensitive quantification of PSA of 0.5 ng/mL and also demonstrated multi-glycan 
profiling where the specific lectin (SNA) could differentiate response from control lectin (MAA II) at 
fPSA concentration down to 3 ng/mL.  
The study addresses how the use of aptamers could be an effective methodology to handle the current 
antibody limitations with cross reactivity issues in glycoprofiling. It also shows how aptamers could 
be used as a potential tool for multi-glycan profiling of biomarkers with high sensitivity and 
selectivity in a simple microfluidic channel. This approach can be easily extended to a wide range of 
other biomarkers available for PCa, a step towards multiplexing, which is of great interest for PCa 
diagnosis. The simultaneous detection of protein cancer biomarkers together with their levels of 
glycosylation provides enhanced diagnosis and prognosis of the disease. 
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